Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SELECT: Lenvatinib in 131I-Refractory Differentiated Thyroid Cancer
NCT01321554Phase 3Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Mar 2011
- Primary completion
- Nov 2013
- Modality
- Small Molecules
- Countries
- 23
01
Overview
A Phase 3 trial of lenvatinib in differentiated thyroid cancer (DTC), sponsored by Eisai Co., Ltd.. Started Mar 2011; status: completed.
02
Drugs
lenvatinib
03
Conditions
differentiated thyroid cancer (DTC)
Beyond the preview
Go deeper on NCT01321554.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01321554.